Coherus Q3 Revenue Misses at $14.3M, Net Loss Widens to $39.3M
CHRS is trading near its 52-week low of $0.732 (5.2% above the low).
Summary
Coherus reported Q3 revenue of $14.274 million, well short of the $16 million IBES estimate — a roughly 11% miss. The bottom line was ugly: net loss of $39.334 million, operating loss of $33.649 million, and adjusted net loss of $31.205 million. That revenue figure is barely above the $13.6 million LOQTORZI run rate disclosed in the Q2 10-Q, so the top line is essentially flat while losses stay heavy. With the stock at $0.77 and a market cap near $126 million, the company is leaning on its $50M ATM and the ongoing biosimilar asset sale to fund operations, and it has announced a strategic prioritization plan that lowers the LOQTORZI revenue needed for core burn to $25M-$30M. The interim tagmokitug data from late October (75% confirmed response rate in untreated esophageal cancer) remains the pipeline story, but this quarter shows no financial cushion from it yet.
At the time of this announcement, CHRS was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.3M. The 52-week trading range was $0.73 to $2.62. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.